Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 11/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202486 | 0.82 | TLR7 (0.45) | KDM5BTLR7TLR8ADORA3ADORA2A | |
| SCHEMBL203571 | 0.77 | KDM5B (0.39) | KDM5B | |
| SCHEMBL10123111 | 0.70 | PRMT5 (0.50) | PRMT5HRH4TLR7TLR8DHFR | |
| SCHEMBL4299811 | 0.69 | TLR7 (0.42) | PRMT5CDK1CDK2MKNK1MKNK2 | |
| SCHEMBL204390 | 0.69 | PRMT5 (0.42) | PRMT5CDK1CDK2MKNK1MKNK2 | |
| SCHEMBL202005 | 0.69 | KDM4E (0.42) | PRMT5CDK1CDK2MKNK1MKNK2 | |
| SCHEMBL311681 | 0.67 | PRMT5 (0.42) | PRMT5CDK1CDK2MKNK1MKNK2 | |
| SCHEMBL30413516 | 0.67 | PRMT5 (0.42) | PRMT5CDK1CDK2MKNK1MKNK2 | |
| SCHEMBL13588390 | 0.67 | PRMT5 (0.47) | PRMT5HRH4TLR7TLR8 | |
| SCHEMBL5809073 | 0.67 | PRMT5 (0.43) | PRMT5HRH4TLR7TLR8ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | PRMT5 959/4885KDM5B 1686/4885CDK1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.